Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
Healthcare
$22.98 +0.34%
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
52W Low $2.45High $38.33
Volume 0.58M
Average 0.33M
Balance Sheet
Inspect the capital base behind the business.
Assets
$260.53M
FY 2025 · Annual
+1420.7% YoYLiabilities
$20.15M
FY 2025 · Annual
+657.1% YoYEquity
$240.38M
FY 2025 · Annual
+1561.1% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62.56M | 32.79M | 21.47M | 14.18M | 257.62M |
| Short-term Investments | 37.63M | 27.44M | 11.69M | 0 | 0 |
| Net Receivables | 2.28M | 1.38M | 1.72M | 881K | 899K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.9M | 1.5M | 1.13M | 1.19M | 1.32M |
| Total Current Assets | 110.1M | 63.91M | 36.77M | 16.84M | 260.42M |
| Property, Plant & Equipment (Net) | 1.04M | 1.17M | 325K | 130K | 104K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 9.05M | 5.83M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.03M | 2.28M | 1.13M | 163K | 0 |
| Total Non-current Assets | 12.11M | 9.28M | 1.45M | 293K | 104K |
| Total Assets | 122.22M | 73.19M | 38.23M | 17.13M | 260.53M |
| Account Payables | 1.53M | 3.35M | 1.7M | 377K | 444K |
| Short-term Debt | 399K | 476K | 183K | 12K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.01M | 6.68M | 2.96M | 604K | 1.52M |
| Total Current Liabilities | 4.54M | 11.11M | 5.83M | 1.2M | 20.07M |
| Long-term Debt | 0 | 0 | 0 | 1.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 43K | 28K |
| Total Non-current Liabilities | 448K | 328K | 66K | 1.46M | 81K |
| Total Liabilities | 4.99M | 11.44M | 5.9M | 2.66M | 20.15M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (156.11M) | (217.74M) | (256.08M) | (277.52M) | (487.36M) |
| Accumulated OCI | (320K) | (244K) | 380K | 97K | 802K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 117.22M | 61.75M | 32.33M | 14.47M | 240.38M |
| Total Debt | 847K | 804K | 249K | 1.43M | 68K |
| Net Debt | (61.72M) | (31.98M) | (21.22M) | (12.74M) | (257.56M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $532.9M |
| Receivables | $894.0K |
| Other Current | $1.6M |
| Total Current Assets | $535.4M |
| Other Non-current | $34.0K |
| Total Non-current Assets | $34.0K |
| Total Assets | $535.4M |
Analysis
Selected assets total $535.4M for Latest. The largest visible component is Cash & Equivalents at $532.9M, about 99.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 13, 2026 | |
| 3 | Initial statement of beneficial ownership | Aug 13, 2026 | |
| EFFECT | EFFECT filing | Aug 12, 2026 |
How much cash does DMRA have?
Damora Therapeutics, Inc. (DMRA) reported $257.62M in cash and equivalents in fiscal 2025.
How much debt does DMRA carry?
Damora Therapeutics, Inc. (DMRA) reported $68,000.00 of total debt, with net debt of -$257.56M.
Continue the stock analysis
Jump to another research area for this company.